Abstract
Importance Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role in Alzheimer’s disease and several other neurodegenerative syndromes. Anti-tau antibodies can reduce pathology in mouse models of neurodegeneration and are currently being tested in humans.
Objective To evaluate the seroprevalence of natural anti-tau autoantibodies and their potential association with diseases.
Design In a cross-sectional study, plasma samples from a randomized university hospital cohort and healthy blood donors, collected from 2017 to 2020, were screened for anti-MTBD-tau plasma IgG autoantibodies (ατ) in a miniaturized, high-throughput ELISA. Samples were included if basic demographic data was available and age was ≥18 years. Data analysis was performed from De-cember 2017 to August 2024. Titers were defined as −log10(EC50) values. Titers of ≥1.8 were clas-sified as ατ+.
Participants Blood was obtained during routine clinical care from 32,291 patients admitted as inpatients or outpatients to any department of a university hospital, or from 8,206 healthy blood donors.
Results High-titer ατ+ samples were surprisingly prevalent, with hospital patients being three times more likely to be ατ+ than healthy blood donors (4.8% vs 1.6%). ατ autoantibodies ligated selectively tau, inhibited tau aggregation in vitro, and interfered with tau detection in plasma sam-ples. No association was found between ατ autoantibodies and neurologic disorders. Instead, tau autoreactivity showed a significant association with kidney and urinary disorders (adjusted risk ratio (RR) 1.27, 95% CI 1.10-1.45, P=0.001 and 1.40, 95% CI 1.20-1.63, P<0.001 respectively).
Conclusions and Relevance While ατ autoimmunity was not associated with neurologic dis-eases, its association with extraneural pathologies will require scrutiny in the context of anti-tau therapies. Moreover, immunochemical plasma tau assays were confounded by ατ antibodies, whose high prevalence may limit their usefulness as biomarker.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ADM has received a research grant from University of Zurich; KF has received research grants from Ono Pharmaceuticals and Theodor Ida Herzog Egli Stiftung, consulting fees from Acumen Collective and Ionis Pharmaceuticals, support for attending meetings/travel from Euro-CNS and has participated on the Advisory Board of Mabylon AG; AA has received research grants from the Swiss Personalised Health Network, Swiss National Foundation, European Research Council and Nomis Foundation and is a member of the Board of Directors of Mabylon AG. Mabylon AG produces therapeutic human antibodies. Mabylon AG had no insight and no influence on the current study. All authors report no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study was supported by a Candoc grant (FK-19-025) of the University of Zurich to ADM, by grants of the Swiss Personalised Health Network (SPHN, driver project grant 2017DRI17), Swiss National Foundation SNF (SNSF grant ID 179040 and grant ID 207872, Sinergia grant ID 183563), the European Research Council (ERC Prion2020, 670958), Innovation Fund of the University Hospital Zurich (INOV00096), HMZ ImmunoTarget grant, Stiftung Neuropath and GELU Foundation to AA and the University Hospital Zurich Foundation grant USZF27101 (with contributions of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung) to AA and ME.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Collection of samples and clinical data were conducted according to study protocols approved by the Cantonal Ethics Committee of the Canton of Zurich, Switzerland.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update the following: The manuscript has been shortened and reorganized.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
